The International Diabetes Federation (IDF) is pleased to welcome Biocon Biologics as a new partner, the first biosimilar insulins company to promote and support IDF’s core mission and activities.
This partnership strengthens our shared vision of achieving universal access to insulin globally, tackling a broad range of diabetes issues, creating awareness and educating and advocating for effective management of diabetes.
“It is with great pleasure that IDF welcomes Biocon Biologics as a new partner. It is an important time for diabetes. This year, we celebrate the centenary of the development of therapeutic insulin in 1921 and next year its first successful use to treat a person with diabetes in 1922. Yet, 100 years after its discovery, this life-saving drug remains beyond the reach of many people with diabetes who need it. For IDF and our partners, the centenary of insulin will provide opportunities to raise awareness of diabetes, promote action to improve access to diabetes care and encourage greater effort to prevent diabetes and its complications,” said Prof. Andrew Boulton, President of IDF.
“We are delighted to partner with the International Diabetes Federation and contribute to a stronger global voice for people living with diabetes. As a leading global insulins player, we have a shared vision of finding viable, long-term solutions to improve insulin access and affordability. Given our extensive experience in providing affordable insulins globally, we believe we can contribute and support IDF in driving real policy and access actions that will transform lives and diabetes care,” said Dr Alexander Zach, Global Head of Market Access & Policy, Biocon Biologics.
